Wisconsin Collaborative for Quality Healthcare

View Our Reports

print this page

Ischemic Vascular Disease: Daily Aspirin or Other Antiplatelet Therapy Unless Contraindicated This is a measure developed by the Wisconsin Collaborative for Healthcare Quality (WCHQ).

Your Search Results: 31 Clinics in the Prevea Health health system


The results below represent the care of 2,413 patients with coronary and other atherosclerotic vascular disease. Read More About This Measure

Reporting Period:

Sort By Rank | Sort By Name  
Btn Export
Prevea Health - Allouez
N=220
74.55 %
View Historical Data
Prevea Health - Arcadia

The number of patients or providers is too small for
purposes of reliably reporting performance
Prevea Health - Ashwaubenon
N=228
73.25 %
View Historical Data
Prevea Health - Chippewa Falls

The number of patients or providers is too small for
purposes of reliably reporting performance
Prevea Health - Cornell

The number of patients or providers is too small for
purposes of reliably reporting performance
Prevea Health - East DePere
N=426
80.28 %
View Historical Data
Prevea Health - East Mason
N=323
69.66 %
View Historical Data
Prevea Health - Eau Claire

The number of patients or providers is too small for
purposes of reliably reporting performance
Prevea Health - Gillett

The number of patients or providers is too small for
purposes of reliably reporting performance
Prevea Health - Howard
N=508
71.85 %
View Historical Data
Prevea Health - HWC

The number of patients or providers is too small for
purposes of reliably reporting performance
Prevea Health - Kewaunee

The number of patients or providers is too small for
purposes of reliably reporting performance
Prevea Health - Lena

The number of patients or providers is too small for
purposes of reliably reporting performance
Prevea Health - Luxemburg

The number of patients or providers is too small for
purposes of reliably reporting performance
Prevea Health - Marinette

The number of patients or providers is too small for
purposes of reliably reporting performance
Prevea Health - Menomonie

The number of patients or providers is too small for
purposes of reliably reporting performance
Prevea Health - Mountain

The number of patients or providers is too small for
purposes of reliably reporting performance
Prevea Health - Oconto
N=120
75.00 %
View Historical Data
Prevea Health - Oconto Falls

The number of patients or providers is too small for
purposes of reliably reporting performance
Prevea Health - On-Site Clinic

The number of patients or providers is too small for
purposes of reliably reporting performance
Prevea Health - Osseo

The number of patients or providers is too small for
purposes of reliably reporting performance
Prevea Health - Plymouth

The number of patients or providers is too small for
purposes of reliably reporting performance
Prevea Health - Pulaski
N=124
68.55 %
View Historical Data
Prevea Health - Seymour

The number of patients or providers is too small for
purposes of reliably reporting performance
Prevea Health - Shawano Avenue

The number of patients or providers is too small for
purposes of reliably reporting performance
Prevea Health - Sheboygan

The number of patients or providers is too small for
purposes of reliably reporting performance
Prevea Health - St. Mary's
N=281
73.31 %
View Historical Data
Prevea Health - St. Vincent

The number of patients or providers is too small for
purposes of reliably reporting performance
Prevea Health - Vernon Dr.

The number of patients or providers is too small for
purposes of reliably reporting performance
Prevea Health - Washington St.

The number of patients or providers is too small for
purposes of reliably reporting performance
Prevea Health - West DePere
N=183
64.48 %
View Historical Data

There has been important evidence from clinical trials that further supports and broadens the merits of risk-reduction therapies for patients with established coronary and other atherosclerotic vascular disease, including peripheral arterial disease, atherosclerotic aortic disease, and carotid artery disease.

Based on trials involving other secondary prevention therapies, the ACC and AHA recommends aspirin in all patients, unless contraindicated, with established coronary and other atherosclerotic vascular disease, including peripheral arterial disease, atherosclerotic aortic disease, and carotid artery disease. The ACC and AHA also recommend the use of other antiplatelet agents based on disease type and clinical conditions.

This measure shows the percentage of people 18 to 75 years of age with a diagnosis coronary or other atherosclerotic vascular disease who were prescribed oral antiplatelet therapy, unless contraindicated, in the measurement year.


Disclaimer: Measures reported by WCHQ healthcare organizations represent a specific aspect of care in relation to an evidence-based standard, but are not clinical guidelines and do not establish standards of care.